History

GeneWerk’s journey began long before the company was officially founded in 2014 by Prof. Dr. Christof von Kalle, Dr. Manfred Schmidt and Dr. Annette Deichmann as an academic spin-off of the German Cancer Research Center (DKFZ).

2021

PPS merges with GeneWerk.

Check out our recent press release

2020

GeneWerk secured a growth equity investment from Ampersand Capital Partners and established its US entity.

2014

GeneWerk GmbH was founded in July 2014 by Prof. Dr. Christof von Kalle, Dr. Manfred Schmidt and Dr. Annette Deichmann.

2013

GeneWerk’s founding team was involved in the safety assessment of Glybera, the first approved gene therapy drug in a western country.

2010

Gene therapy safety testing fee-for-service initiated at the German Cancer Research Center (DKFZ), Heidelberg, Germany.

2001

GeneWerk’s founding team was involved in the identification of retroviral integration-related serious adverse events (SAEs) in X-linked severe combined immunodeficiency (X-SCID) patients.

1998

LAM-PCR, the then gold standard for vector integration site analysis developed by Dr. Manfred Schmidt, was used in the first Europe-wide gene marking trial in Chronic Myelogenous Leukemia (CML) patients.

Join us

We are driven by patient safety. This means our people have the opportunity to make a difference. Join us to work with renowned gene therapy innovators from around the world to make the next breakthrough a clinical reality.

View vacancies

Meet the team

Meet our team

Dr. Manfred Schmidt

CEO
View bio

Dr. Annette Deichmann

Managing Director
View bio

Dr. Wei Wang

Head of Business Development
View bio
Meet our team
I agree to the Privacy Policy and Terms of Service.